Overview

Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

Status:
Completed
Trial end date:
2017-01-12
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of an approximate 1.5 mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
Phase:
Phase 3
Details
Lead Sponsor:
Almirall, S.A.
Warner Chilcott
Collaborator:
Allergan
Treatments:
Sarecycline